

Pharmacokinetics of Injectable Beta – Cyclodextrin - Oridonin Inclusion Complex, A Novel Formulation of Oridonin in Wistar Rats

Bao-qiu Li¹, Na Li², Shu-juan Wang³, Ji-you Gao², Shi-hong Fang²

¹ Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44, Wen Hua Xi Road, Jinan, Shandong- 250012, China

² Shandong Hongli Laboratory Animal Experiment Co., Ltd., A502 No.750 Shun Hua Road, Jinan, Shandong- 250101, China

³ A-Think Pharmaceutical Co., Ltd. Changchun, Jilin- 130616, China

Correspondence to:

Bao-qiu Li
(liqiu@163169.net)

Received: 18.07.2011

Accepted: 04.08.2011

ABSTRACT

Aims: Oridonin is a new anti-tumor drug candidate with promising broad spectrum antitumor activity. The aim of the present study is to investigate the single- and repeated-dose pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex in rats.

Materials and methods: Rats were given single- or multiple-dose (7 days) of injectable beta-cyclodextrin-oridonin inclusion complex (single-dose: 33 mg/m², 99 mg/m², 296 mg/m²; repeated-dose: 99 mg/m² calculated as oridonin) by intravenous injection. Plasma Oridonin was analyzed by LC-ESI-MS. The main pharmacokinetics parameters were calculated and compared.

Results: The PK data of single-dose injectable beta-cyclodextrin-oridonin inclusion complex in rats were best fit by a three-compartment model. The terminal elimination half-life (t_{1/2z}) of oridonin ranged from 8.72±1.14 to 10.87±2.03h. AUC (0-t) and C_{max} for oridonin showed statistically significant differences (p < 0.05) between single dose and repeated dose.

Conclusion: Our study has led to the view that injectable beta-cyclodextrin-oridonin inclusion complex can increase the bioavailability of oridonin in rats and is suitable for once a day dosing. However, caution should be taken with when injectable beta-cyclodextrin-oridonin inclusion complex is given by i.v. repeatedly.

KEY WORDS: Pharmacokinetics; Oridonin; Beta-cyclodextrin; Rats


INTRODUCTION

Chinese herbal medicine is widely used in China and plays an important role in the prevention and treatment of various kinds of human diseases. Some compounds extracted from Chinese medicinal herbs shows promising biological and pharmacological activities, such as artemisinin, paclitaxel and salvianolic acid.^[1-5] For example, artemisinin have been used worldwide as an antimalarial agent and paclitaxel has been successfully used in the clinic as an antitumor agent.

Rabdosia rubescens is a Chinese medicinal herb which has been approved by State Food and Drug Administration of China for the treatment of inflammation such as acute tonsillitis, sphaigitis, astomatitis and gingivitis.^[6] It has also been used in folk medicine in China for the treatment of esophageal and cardia cancer.

Over the past thirty years, considerable in vitro and animal studies have been performed to determine the active ingredient of *Rabdosia rubescens* and the precise mechanism responsible for its antitumor activity.

Figure-1: Structural formula of oridonin



It is found that oridonin (Figure 1), an ent-kaurane diterpenoid derived from the herbal *Rabdosia rubescens* inhibit the proliferation of human nasopharyngeal carcinoma CNE2 cells^[7], human gastric cancer MKN45 cells^[8], U937 cells^[9], HeLa cells^[10], murine fibrosarcoma L929 cells^[11], human laryngeal carcinoma HEp-2 cells^[12], HT1080 cells^[13], human hepatocellular carcinoma BEL-7402 cells^[14], human melanoma

A375-S2 cells^[15], leukemia K562 cells^[16] and some other tumor cells. Preliminary animal data demonstrate that oridonin can significantly reduce the volume of sarcoma-180 solid tumors in mice^[11] and prolong survival of leukemia mice models.^[18]

All these findings indicate that oridonin is a new anti-tumor drug candidate with promising broad spectrum antitumor activity. However, oridonin is insoluble in water and has a very bitter taste. The absolute bioavailability of oridonin following oral administration and intraperitoneal administration were rather low.^[19] Limited data are available concerning the toxicokinetics of oridonin.

Injectable beta-cyclodextrin-oridonin inclusion complex (freeze dried powder) is a new formulation of oridonin prepared by A-Think Pharmaceutical Co., Ltd The aim of the present study is to investigate the pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex in rats following intravenous injection.

MATERIALS AND METHODS

Chemicals and Reagents

Injectable beta-cyclodextrin-oridonin inclusion complex (freeze dried powder; entrapment efficiency: 86.01±4.33%; average particle size: 392 nm) was supplied by A-Think Pharmaceutical Co., Ltd. (Changchun, China). Oridonin was purchased from Chinese national institute for the control of pharmaceutical and biological products (Beijing, China). Ethyl p-Hydroxybenzoat (internal standard) was purchased from Sinopharm chemical reagent Beijing Co., Ltd. Normal saline (0.9% NaCl) was purchased from Shandong hualu pharmaceutical Co., Ltd (Liaocheng, Chian). Heparin was purchased from Changzhou Qianhong Bio-pharm Co., Ltd. (Changzhou, China).

Animals

Two hundred and twenty-two specified-pathogens free Wistar rats (111 male, 111 female) weighted 180-220g, were obtained from the Experimental Animal Center of Shandong

University (Jinan, China) and quarantined for 1 week. The rats were housed in stainless steel wire-mesh cages under specific pathogen free conditions (12h day/night cycle, temperature 22–24°C, humidity 52–58%).

The study protocol was approved by the Animal Ethics Committee of Shandong Hongli Laboratory Animal Experiment Co., Ltd. All aspects of the study involving animal procurement, care, housing, use, disposal and welfare were performed in compliance with Chinese regulations for the care and use of experimental animals.

LC-ESI-MS

Oridonin levels in plasma were analyzed by LC-ESI-MS. The HPLC was equipped with a SPD-10A ultraviolet detector, a Shim-Pack VP-ODS C18 column (150 mm × 2.0 mm I.D., 5 µm particle size) and a Shim-pack GVP-ODS C18 guard column (5 mm × 2.0 mm I.D., 5 µm particle size) purchased from Shimadzu (Tokyo, Japan). The column temperature was kept at 40°C. The mobile phase was a mixture of acetonitrile and water (50:50, V/V) and pumped at a flow rate of 0.2 ml/min.

The mass spectrometer was operated in negative ESI model with the following conditions: CDL temperature of 250°C, CDL voltage of 15V, block heater temperature of 200°C, nebulizing gas (N₂) flow rate of 1.5L/min, drying gas pressure of 0.1MPa and probe voltage of 1.6kV. Monitor ions for SIM analysis were m/z 363 for oridonin (M-H-) and m/z 165 for ethyl p-Hydroxybenzoat (M-H-).

Preparation of Biological Samples

Blood samples were collected, anticoagulated with heparin, centrifuged at 3000rpm for 10 min to obtain plasma and stored at -80°C (Forma Scientific Bio-freezer, Marietta, Ohio, USA) until analysis. For quantitative analysis, the plasma (50µl) was spiked with ethyl p-Hydroxybenzoat (2µg/ml, internal standard), deproteinized with methanol, vortexed for 15 s using a vortex mixer (IKA, Staufen, Germany) and centrifuged at 1000rpm for 10 min. Then 5 µl of the

supernatant was injected into the LC-ESI-MS system.

Single-Dose PK Study

Two hundred and sixteen Wistar rats (108 male, 108female) were randomly divided into 3 groups after an overnight fast and given three different dose of injectable beta-cyclodextrin-oridonin inclusion complex (296 mg/m², 99 mg/m² and 33 mg/m² respectively, calculated as oridonin) by intravenous injection.

Blood samples were collected 5 min, 10 min, 30 min, 1h, 2h, 4h, 8h, 12h, 16h, 24h, 36h and 48h postdose and subsequently treated and analyzed by the method above.

Repeated-Dose PK Study

Six rats were given injectable beta-cyclodextrin-oridonin inclusion complex (99 mg/m², calculated as oridonin) by intravenous injection once a day for 7 days. Blood samples of rats were collected at prodose (day 4, day 5, day 6 and day 7), 0.5, 1, 2, 8 and 24h after the last injection.

Curve fitting and PK parameters calculation were performed using the DAS version 2.0 pharmacokinetic program (Chinese Pharmacology Society, Beijing, China). The peak concentration (C_{max}) and time to peak concentration (T_{max}) for oridonin were determined from the actual measurements. The area under the concentration-time curve (AUC) was calculated by using the linear trapezoidal rule.

Statistics Analysis

Main PK parameters were calculated by DAS 2.1.1. Values were expressed as mean ±SD. Statistical significance in inter-group comparison was analyzed by Student's t-test.

RESULTS

Single-dose PK of injectable beta-cyclodextrin-oridonin inclusion complex in rats

The mean concentration-time profiles and PK parameters of single-dose injectable beta-cyclodextrin-oridonin inclusion complex in rats

were shown in Figure 2 and Table 1 respectively. The PK data of single-dose injectable beta-cyclodextrin-oridonin inclusion complex in rats were best fit by a three-compartment model. AUC and C_{max} of oridonin increased proportionally when the dose of oridonin was escalated. The terminal elimination half-life ($t_{1/2z}$) of oridonin ranged from 8.72 ± 1.14 to 10.87 ± 2.03 h.

Repeated-dose PK of injectable beta-cyclodextrin-oridonin inclusion complex in rats

The mean concentration-time profiles and PK parameters of repeated-dose injectable beta-cyclodextrin-oridonin inclusion complex in rats following intravenous injection were shown in Figure 3 and Table 1 respectively. AUC_(0-t) and

C_{max} for oridonin showed statistically significant differences ($p < 0.05$) between singledose and repeated dose.

DISCUSSION

Many natural products display beneficial anticancer effects in vitro. But only a few have been used in clinical practice.

Oridonin is extracted and purified from *Rabdosia rubescens*, one of the most important traditional Chinese herbs commonly used in China nowadays. It has been studied exclusively by several groups in China and has been shown to possess anti-tumor activity.^[20-21] However, limited data are available concerning the toxicokinetics of oridonin.

Table-1: PK parameters of single- and repeated-dose of injectable beta-cyclodextrin-oridonin inclusion complex following intravenous injection

PK Parameters	Single-Dose			Repeated-Dose 99 mg/m ²
	33 mg/m ²	99 mg/m ²	296 mg/m ²	
AUC _(0-t) (ng/ml·h)	511.49±27.03	1507.57±50.52	7002.75±421.67	5175.81±85.40*
AUC _(0-∞) (ng/ml·h)	563.54±12.64	1586.12±65.08	7280.37±240.0	5364.07±49.57*
MRT _(0-t) (h)	3.21±0.40	4.25±1.62	5.88±1.03	5.20±0.48
MRT _(0-∞) (h)	4.52±0.51	5.15±0.19	7.60±2.30	6.12±2.54
$t_{1/2z}$ (h)	8.72±1.14	8.45±0.98	10.87±2.03	10.27±1.69
T_{max} (h)	0.17±0.05	0.17±0.02	0.17±0.06	0.50±0.01
V_z (l/m ²)	314.63±12.15	400.66±3.94	614.44±23.06	140.25±6.49
CL_z (l/h/m ²)	58.56±11.27	62.42±9.68	40.66±10.11	18.46±6.88
C_{max} (ng/ml)	420.87±3.10	1097.43±14.67	3032.40±89.20	1337.50±102.54

Six rats were used in the repeated-dose PK study and were given injectable beta-cyclodextrin-oridonin inclusion complex (99 mg/m², calculated as oridonin) by intravenous injection once a day for 7 days. Mean ±SD; * $p < 0.05$ vs. first injection (day 1); Single-dose: n=6; Repeated-dose: n=6

Figure-2: Concentration-time profile of single dose injectable beta-cyclodextrin-oridonin inclusion complex in rats following intravenous injection





Figure-3: Concentration-time profile of repeated-dose (99mg/m²) injectable beta-cyclodextrin-oridonin inclusion complex in rats following intravenous injection



In the present study, we investigated the PK of injectable beta-cyclodextrin-oridonin inclusion complex (freeze dried powder), a new preparation of oridonin, in rats.

The AUC and C_{max} of single- and repeated-dose of injectable beta-cyclodextrin-oridonin inclusion complex were significantly higher than that of common oridonin injection.^[22] It indicates that the beta-cyclodextrin-oridonin inclusion complex can increase the solubility and bioavailability of oridonin. Based on the ED_{50} of oridonin^[23], high levels oridonin in rats observed in the present study is helpful to exert its anticancer activity in vivo.

The terminal elimination half-life ($t_{1/2z}$) of three doses of injectable beta-cyclodextrin-oridonin inclusion complex showed no significant difference when compared with oridonin tablet and common oridonin injection.^[22] It is long enough for once a day dosing. AUC_(0-t) and C_{max} for oridonin showed significant differences between singledose and repeated dose. Thus, caution should be taken with when njectable beta-cyclodextrin-oridonin inclusion complex is given by i.v. repeatedly.

CONCLUSION

Injectable beta-cyclodextrin-oridonin inclusion complex can increase the solubility and bioavailability of oridonin in rats and is suitable for once a day dosing. However, caution should be taken with when njectable beta-cyclodextrin-oridonin inclusion complex is given by i.v. repeatedly.

ACKNOWLEDGEMENT

The authors would like to thank Dr. Xian-Jun Qu for his valuable assistance in the preparation of the manuscript.

REFERENCES

1. Avery MA, Muraleedharan KM, Desai PV, Bandyopadhyaya AK, Furtado MM, Tekwani BL (2003) Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria. *J Med Chem* 46:4244-4258.
2. Van Nieuwerburgh FC, Vande Castele SR, Maes L, Goossens A, Inzé D, Van Bocxlaer J, Deforce DL (2006) Quantitation of artemisinin and its biosynthetic precursors in *Artemisia annua* L. by high performance liquid chromatography-electrospray quadrupole time-of-flight tandem mass spectrometry. *J Chromatogr A* 1118: 180-187.
3. Liu CH, Hu YY, Wang XL, Liu P, Xu LM (2000) Effects of salvianolic acid-A on NIH/3T3 fibroblast proliferation, collagen synthesis and gene expression. *World J Gastroenterol* 6:361-364.
4. Wang RP, Liu C, Liu P, Zhu DY (2000) Protective actions of salvianolic acid A on hepatocyte injured by peroxidation in vitro. *World J Gastroenterol* 6:402-404.
5. Gaitanis A, Staal S (2010) Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. *Methods Mol Biol* 624: 385-392.
6. Chen S, Liu J, Zhang H (2009) Efficacy of *rabdosia rubescens* in the treatment of gingivitis. *J Huazhong Univ Sci Technolog Med Sci* 29:659-663.
7. Xiao DJ, Zhu GC, Wang XL (2007) Effects of Oridonin on proliferation in human nasopharyngeal carcinoma line CNE 2 in vitro. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 42:780-782.
8. He XJ, Wang HJ, Xia YJ, Ye ZY, Tao HQ (2009) Empirical study of oridonin-induced gastric cancer cells MKN45 apoptosis. *Zhonghua Wei Chang Wai Ke Za Zhi* 12:607-610.
9. Liu YQ, You S, Tashiro S, Onodera S, Ikejima T (2005) Oridonin induced U937 cell apoptosis through ERK pathway. *Zhongguo Zhong Yao Za Zhi* 30:1856-1859.
10. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T (2004) Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway. *Acta Pharmacol Sin* 25:691-698.

11. Cheng Y, Qiu F, Ikejima T (2009) Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. *Autophagy* 5:430-431.
12. Kang N, Zhang JH, Qiu F, Chen S, Tashiro S, Onodera S, Ikejima T (2010) Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. *J Nat Prod* 73:1058-1063.
13. Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S, Ikejima T (2009) NF-kappaB facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. *Arch Biochem Biophys* 489:25-33.
14. Zhang JF, Liu JJ, Liu PQ, Lin DJ, Li XD, Chen GH (2006) Oridonin inhibits cell growth by induction of apoptosis on human hepatocellular carcinoma BEL-7402 cells. *Hepatol Res* 35:104-110.
15. Wang HJ, Li D, Yang FY, Tashiro S, Onodera S, Ikejima T (2008) Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. *J Asian Nat Prod Res* 10: 787-798.
16. Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, Song YQ, Lin Q, Hou M, Wang DN, Chen F, Zhang MH (2005) Oridonin-induced apoptosis in leukemia K562 cells and its mechanism. *Neoplasma* 52:225-230.
17. [17] Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q (2009) In vitro and in vivo antitumor activity of oridonin nanosuspension. *Int J Pharm* 379: 181-186.
18. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z (2007) Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. *Blood* 109:3441-3450.
19. Xu W, Sun J, Zhang TT, Ma B, Cui SM, Chen DW, He ZG (2006) Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. *Acta Pharmacol Sin* 27:1642-1646.
20. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM (2005) Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponidicin and oridonin, diterpenoids from the chinese herb *Rabdosia rubescens*. *Biochem Biophys Res Commun* 337:224-230.
21. Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC, Zhang RQ (2006) The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. *J Ethnopharmacol* 103:176-180.
22. Xu W, Sun J, Zhang TT, Ma B, Cui SM, Chen DW, He ZG. (2006) Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. *Acta Pharmacol Sin* 27:1642-1646.
23. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H (2005) Oridonin, a diterpenoid purified from *Rabdosia rubescens*, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. *Mol Cancer Ther* 4:578-586.

Source of Support: Nil

Conflict of interest: None declared